LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that it has signed a definitive agreement to purchase the assets of six imaging centers in the greater Houston, Texas metropolitan area. This acquisition, which is anticipated to be completed before the end of the second quarter of 2024, is RadNet’s second announced transaction in Houston, and upon closing, will bring the number of RadNet centers in this geography to 13. The previously announced acquisition of seven imaging centers from Houston Medical Imaging, LLC was completed on April 1st, 2024.
The six multimodality centers to be acquired offer a broad range of imaging services, including MRI, CT, mammography, ultrasound and x-ray, and currently operate under the American Health Imaging brand. Shortly after the completion of the acquisition, we intend to transition the branding of these centers to Houston Medical Imaging. RadNet anticipates that the acquired centers will add over 100,000 procedures and $15 million of revenue on an annual basis.
RadNet’s President and Chief Executive Officer, Howard Berger, MD explained, “We are excited to announce our second transaction in Houston, where RadNet can provide the patients and referring physicians of the greater Houston area increased access to high-quality, cost-effective outpatient diagnostic imaging services. Houston encompasses about 7.3 million people, making it the fourth most populous city and the second fastest growing metropolitan area in the United States. Houston presents an exciting opportunity for further growth, including de novo build-outs and potential health system partnerships, and we plan to introduce our AI and digital health solutions to the patient and referring communities in the near future.”
The asset acquisition is subject to customary closing conditions.
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida and Arizona. Together with affiliated radiologists, including full-time and per diem employees and technologists, RadNet has approximately 9,700 employees. For more information, visit http://www.radnet.com
Forward Looking Statements
This press release contains certain statements that constitute "forward-looking statements" within the meaning of federal securities laws, including statements regarding the effects of the proposed transaction. These statements are based on the assumptions and beliefs of RadNet, Inc. management in light of the information currently available to it. Such statements are indicated by words or phrases such as "accelerate," "create," "committed," "confident," "continue," "deliver," "driving," "expect," "future," "guidance," "positioned," "strategy," "target," "synergies," "trends," and "will." Various uncertainties and other factors could cause actual results to differ materially from those contained in the forward-looking statements. These include the specific risk factors identified in "Risk Factors" in RadNet, Inc.’s annual report on Form 10-K for the last fiscal year and any subsequent filings, as well as the following:
the expected timing and likelihood of completion of the proposed transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory clearance of the proposed transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the acquisition agreement; the inability to consummate the proposed transaction due to the failure to satisfy other conditions to complete the proposed transaction; the ability to identify and recognize the anticipated benefits of the proposed transaction, including anticipated revenue and procedural volumes; and the ability of RadNet, Inc. to successfully integrate the business and related operations; risks related to the potential impact of general economic, political and market factors on the companies or the proposed transaction. The ability of RadNet, Inc. to achieve the goals for the proposed transaction may also be affected by its ability to manage the factors identified above.
The forward-looking statements by RadNet, Inc. included in this press release speak only as of the date the statements were made. RadNet, Inc. does not assume any obligation to update the information contained herein unless required by applicable law. Please refer to the reports and filings of RadNet, Inc. with the Securities and Exchange Commission for a further discussion of the risks and uncertainties that affect it and its business.
Mark Stolper
Executive Vice President and Chief Financial Officer
RadNet, Inc.
310-445-2800
Last Trade: | US$72.70 |
Daily Change: | 1.32 1.85 |
Daily Volume: | 1,062,005 |
Market Cap: | US$5.380B |
December 04, 2024 December 02, 2024 December 02, 2024 December 01, 2024 December 01, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB